Outcomes in patients (Pts) with advanced prostate cancer and inactivating germline mutations in BRCA2 or ATM.
Steven Yip(University of Calgary), Kim N.(Asian Institute of Technology), Daniel Khalaf(BC Cancer Agency), Matti Annala(Tampere University), Alexander W. Wyatt(University of British Columbia), Gillian Vandekerkhove(University of British Columbia), Werner J. Struss(University of British Columbia), Evan W. Warner(Guardant (United States)), Katherine Sunderland(BC Cancer Agency)
Cited by 3
Related Papers
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k